Neutral endopeptidase-resistant C-Type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism

Journal of Pharmacology and Experimental Therapeutics

Volumn 353, Issue 1, 2015, Pages 132-149

  Wendt, Daniel J ^a   Dvorak Ewell, Melita ^a,c   Bullens, Sherry ^a   Lorget, Florence ^a,d   Bell, Sean M ^a   Peng, Jeff ^a   Castillo, Sianna ^a   Aoyagi Scharber, Mika ^a   O'Neill, Charles A ^a   Krejci, Pavel ^b,e   Wilcox, William R ^b,f   Rimoin, David L ^b   Bunting, Stuart ^a  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c ULTRAGENYX PHARMACEUTICAL INC   (United States)

^d GENENTECH INC   (United States)

^e MASARYK UNIVERSITY   (Czech Republic)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMN 111; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE TYPE C; PROTEIN VARIANT; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; FGFR3 PROTEIN, MOUSE;

ACHONDROPLASIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE GROWTH; BONE MICROARCHITECTURE; CNP GENE; CONTROLLED STUDY; CORTICAL BONE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DWARFISM; GENE; GENETIC VARIABILITY; GROWTH PLATE; IN VITRO STUDY; IN VIVO STUDY; JUVENILE ANIMAL; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SIGNAL TRANSDUCTION; TRABECULAR BONE; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD PRESSURE; BONE; DRUG EFFECTS; GENETICS; HEART RATE; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ACHONDROPLASIA; ANIMALS; BLOOD PRESSURE; BONE AND BONES; HEART RATE; HUMANS; INJECTIONS, SUBCUTANEOUS; MACACA FASCICULARIS; MALE; MICE; NATRIURETIC PEPTIDE, C-TYPE; NEPRILYSIN; NIH 3T3 CELLS; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECOMBINANT PROTEINS;

EID: 84928935546     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.218560     Document Type: Article

References (69)

1. Abbey SE and Potter LR (2003) Lysophosphatidic acid inhibits C-type natriuretic peptide activation of guanylyl cyclase-B. Endocrinology 144:240-246.
2. Barr CS, Rhodes P, and Struthers AD (1996) C-type natriuretic peptide. Peptides 17: 1243-1251.
3. Bartels CF, Bükülmez H, Padayatti P, Rhee DK, van Ravenswaaij-Arts C, Pauli RM, Mundlos S, Chitayat D, Shih LY, Al-Gazali LI, et al. (2004) Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 75:27-34.
4. Bocciardi R, Giorda R, Buttgereit J, Gimelli S, Divizia MT, Beri S, Garofalo S, Tavella S, Lerone M, Zuffardi O, et al. (2007) Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. Hum Mutat 28:724-731.
5. Brandt RR, Heublein DM, Aarhus LL, Lewicki JA, and Burnett JC (1995) Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide. Am J Physiol 269:H326-H331.
6. Brandt RR, Mattingly MT, Clavell AL, Barclay PL, and Burnett JC, Jr (1997) Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo. Hypertension 30:184-190.
7. Charles CJ, Espiner EA, Richards AM, Nicholls MG, and Yandle TG (1995) Biological actions and pharmacokinetics of C-type natriuretic peptide in conscious sheep. Am J Physiol 268:R201-R207.
8. Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, Nakao K, Kurihara T, Komatsu Y, et al. (2001) Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 98:4016-4021.
9. Clavell AL, Stingo AJ, Wei CM, Heublein DM, and Burnett JC, Jr (1993) C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol 264: R290-R295.
10. Dunnett CW and Crisafio R (1955) The operating characteristics of some official weight variation tests for tablets. J Pharm Pharmacol 7:314-327.
11. Erdös EG and Skidgel RA (1989) Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 3:145-151.
12. Evans M and Rees A (2002) The myotoxicity of statins. Curr Opin Lipidol 13: 415-420.
13. Foldynova-Trantirkova S, Wilcox WR, and Krejci P (2012) Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat 33:29-41.
14. FuruyaM, Tawaragi Y, Minamitake Y, Kitajima Y, Fuchimura K, Tanaka S, Minamino N, Kangawa K, and Matsuo H (1992) Structural requirements of C-type natriuretic peptide for elevation of cyclic GMP in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 183:964-969.
15. Garcia S, Dirat B, Tognacci T, Rochet N, Mouska X, Bonnafous S, Patouraux S, Tran A, Gual P, Le Marchand-Brustel Y, et al. (2013) Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci Transl Med 5:203ra124.
16. He L, Shobnam N, Wimley WC, and Hristova K (2011) FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism. J Biol Chem 286: 13272-13281.
17. Hecht JT and Butler IJ (1990) Neurologic morbidity associated with achondroplasia. J Child Neurol 5:84-97.
18. Horton WA, Hall JG, and Hecht JT (2007) Achondroplasia. Lancet 370:162-172.
19. Hunt PJ, Richards AM, Espiner EA, Nicholls MG, and Yandle TG (1994) Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab 78:1428-1435.
20. Igaki T, Itoh H, Suga SI, Hama N, Ogawa Y, Komatsu Y, Yamashita J, Doi K, Chun TH, and Nakao K (1998) Effects of intravenously administered C-type natriuretic peptide in humans: comparison with atrial natriuretic peptide. Hypertens Res 21: 7-13.
21. Iwata T, Chen L, Li C, Ovchinnikov DA, Behringer RR, Francomano CA, and Deng CX (2000) A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. Hum Mol Genet 9: 1603-1613.
22. Jin M, Yu Y, Qi H, Xie Y, Su N, Wang X, Tan Q, Luo F, Zhu Y, Wang Q, et al. (2012) A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia. Hum Mol Genet 21: 5443-5455.
23. Kake T, Kitamura H, Adachi Y, Yoshioka T, Watanabe T, Matsushita H, Fujii T, Kondo E, Tachibe T, Kawase Y, et al. (2009) Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice. Am J Physiol Endocrinol Metab 297:E1339-E1348.
24. Kerr MA and Kenny AJ (1974) The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 137:477-488.
25. Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, Prats H, and Wilcox WR (2005) Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci 118:5089-5100.
26. Kurtz A, Aigner A, Cabal-Manzano RH, Butler RE, Hood DR, Sessions RB, Czubayko F, and Wellstein A (2004) Differential regulation of a fibroblast growth factorbinding protein during skin carcinogenesis and wound healing. Neoplasia 6: 595-602.
27. Laederich MB and Horton WA (2010) Achondroplasia: pathogenesis and implications for future treatment. Curr Opin Pediatr 22:516-523.
28. Long S, Wendt DJ, Bell SM, Taylor TW, Dewavrin JY, and Vellard MC (2012) A novel method for the large-scale production of PG-CNP37, a C-type natriuretic peptide analogue. J Biotechnol 164:196-201.
29. Lopez MJ, Garbers DL, and Kuhn M (1997) The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling. J Biol Chem 272: 23064-23068.
30. Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E, Oppeneer T, Wendt DJ, Bell SM, Bullens S, Bunting S, et al. (2012) Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet 91:1108-1114.
31. Lynch SE, Colvin RB, and Antoniades HN (1989) Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest 84:640-646.
32. Maji D, Shaikh S, Solanki D, and Gaurav K (2013) Safety of statins. Indian J Endocrinol Metab 17:636-646.
33. Matsushita M, Kitoh H, Ohkawara B, Mishima K, Kaneko H, Ito M, Masuda A, Ishiguro N, and Ohno K (2013) Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia. PLoS ONE 8:e81569.
34. Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bükülmez H, Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I, et al. (2009) FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum Mol Genet 18:227-240.
35. Modi HN, Suh SW, Song HR, and Yang JH (2008) Lumbar nerve root occupancy in the foramen in achondroplasia: a morphometric analysis. Clin Orthop Relat Res 466:907-913.
36. Moncla A, Missirian C, Cacciagli P, Balzamo E, Legeai-Mallet L, Jouve JL, Chabrol B, Le Merrer M, Plessis G, Villard L, et al. (2007) A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype. Hum Mutat 28:1183-1188.
37. Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, and de Crombrugghe B (2004) Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev 18:290-305.
38. Murdoch JL, Walker BA, Hall JG, Abbey H, Smith KK, and McKusick VA (1970) Achondroplasia-a genetic and statistical survey. Ann Hum Genet 33:227-244.
39. Nakajima H, Ezaki Y, Nagai T, Yoshioka R, and Imokawa G (2012) Epithelialmesenchymal interaction during UVB-induced up-regulation of neutral endopeptidase. Biochem J 443:297-305.
40. Naski MC, Colvin JS, Coffin JD, and Ornitz DM (1998) Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125:4977-4988.
41. Oefner C, D'Arcy A, Hennig M, Winkler FK, and Dale GE (2000) Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J Mol Biol 296:341-349.
42. Ornitz DM and Marie PJ (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16: 1446-1465.
43. Pagel-Langenickel I, Buttgereit J, Bader M, and Langenickel TH (2007) Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy. J Mol Med (Berl) 85:797-810.
44. Peake N, Su N, Ramachandran M, Achan P, Salter DM, Bader DL, Moyes AJ, Hobbs AJ, and Chowdhury TT (2013) Natriuretic peptide receptors regulate cytoprotective effects in a human ex vivo 3D/bioreactor model. Arthritis Res Ther 15:R76.
45. Placone J and Hristova K (2012) Direct assessment of the effect of the Gly380Arg achondroplasia mutation on FGFR3 dimerization using quantitative imaging FRET. PLoS ONE 7:e46678.
46. Potter LR (2011) Natriuretic peptide metabolism, clearance and degradation. FEBS J 278:1808-1817.
47. Potter LR, Abbey-Hosch S, and Dickey DM (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 27:47-72.
48. Potter LR and Hunter T (2001) Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation. J Biol Chem 276:6057-6060.
49. Rimoin DL, Hughes GN, Kaufman RL, Rosenthal RE, McAlister WH, and Silberberg R (1970) Endochondral ossification in achondroplastic dwarfism. N Engl J Med 283:728-735.
50. Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, and Munnich A (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371:252-254.
51. Ruchon AF, Marcinkiewicz M, Ellefsen K, Basak A, Aubin J, Crine P, and Boileau G (2000) Cellular localization of neprilysin in mouse bone tissue and putative role in hydrolysis of osteogenic peptides. J Bone Miner Res 15:1266-1274.
52. Ryan SM, Mantovani G, Wang X, Haddleton DM, and Brayden DJ (2008) Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 5:371-383.
53. Scotland RS, Ahluwalia A, and Hobbs AJ (2005) C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 105:85-93.
54. Sebastian A, Matsushita T, Kawanami A, Mackem S, Landreth GE, and Murakami S (2011) Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal. J Orthop Res 29:375-379.
55. Seymour AA, Mathers PD, Abboa-Offei BE, Asaad MM, and Weber H (1996) Renal and depressor activity of C-natriuretic peptide in conscious monkeys: effects of enzyme inhibitors. J Cardiovasc Pharmacol 28:397-401.
56. Shirley ED and Ain MC (2009) Achondroplasia: manifestations and treatment. J Am Acad Orthop Surg 17:231-241.
57. Toydemir RM, Brassington AE, Bayrak-Toydemir P, Krakowiak PA, Jorde LB, Whitby FG, Longo N, Viskochil DH, Carey JC, and Bamshad MJ (2006) A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am J Hum Genet 79:935-941.
58. Trotter TL and Hall JG; American Academy of Pediatrics Committee on Genetics (2005) Health supervision for children with achondroplasia. Pediatrics 116: 771-783.
59. Veronese FM and Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451-1458.
60. Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, and Hersh LB (1990) The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem 265:14150-14155.
61. Waldman SD, Usmani Y, Tse MY, and Pang SC (2008) Differential effects of natriuretic peptide stimulation on tissue-engineered cartilage. Tissue Eng Part A 14: 441-448.
62. Watanabe Y, Nakajima K, Shimamori Y, and Fujimoto Y (1997) Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11. Biochem Mol Med 61:47-51.
63. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, and Borst P (2003) Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 278:17664-17671.
64. Wynn J, King TM, Gambello MJ, Waller DK, and Hecht JT (2007) Mortality in achondroplasia study: a 42-year follow-up. Am J Med Genet A 143A:2502-2511.
65. Yamashita A, Morioka M, Kishi H, Kimura T, Yahara Y, Okada M, Fujita K, Sawai H, Ikegawa S, and Tsumaki N (2014) Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature 513:507-511.
66. Yamashita Y, Takeshige K, Inoue A, Hirose S, Takamori A, and Hagiwara H (2000) Concentration of mRNA for the natriuretic peptide receptor-C in hypertrophic chondrocytes of the fetal mouse tibia. J Biochem 127:177-179.
67. Yasoda A, Kitamura H, Fujii T, Kondo E, Murao N, Miura M, Kanamoto N, Komatsu Y, Arai H, and Nakao K (2009) Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology 150: 3138-3144.
68. Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, Kurihara T, Rogi T, Tanaka S, Suda M, et al. (2004) Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 10:80-86.
69. Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, Chusho H, Shiota K, Tanaka K, and Nakao K (1998) Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 273:11695-11700.